Candel Therapeutics Highlights Pipeline Progress and Stability

Candel Therapeutics ( (CADL) ) just unveiled an update.

Candel Therapeutics announced a corporate update highlighting strong pipeline momentum and key value drivers for 2025, including the reporting of updated overall survival data for CAN-2409 in pancreatic ductal adenocarcinoma and non-small cell lung cancer, and preparations for a Biologics License Application for CAN-2409 in prostate cancer. The company reported an unaudited cash position of $102.9 million as of December 31, 2024, sufficient to fund operations into Q1 2027, reflecting their financial stability and capacity to pursue ongoing and upcoming clinical trials and regulatory submissions.

More about Candel Therapeutics

Candel Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer. Their pipeline includes investigational medicines targeting prostate cancer, pancreatic cancer, non-small cell lung cancer, and recurrent high-grade glioma, with a focus on viral immunotherapy and novel experimental assets generated using their enLIGHTEN Discovery Platform.

YTD Price Performance: -9.01%

Average Trading Volume: 3,631,803

Technical Sentiment Consensus Rating: Sell

Current Market Cap: $363.8M

Find detailed analytics on CADL stock on TipRanks’ Stock Analysis page.